试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
编号:NCT04200365登记状态:提前终止企业 / 申办者:SCRI Development Innovations, LLC
药物 / 成分:Itacitinib
登记的停止原因(原文):Slow enrollment and PI departure
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
编号:NCT04287894登记状态:提前终止企业 / 申办者:The Netherlands Cancer Institute
药物 / 成分:Durvalumab、Tremelimumab、Pemetrexed、Cisplatin
登记的停止原因(原文):Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
编号:NCT04762875登记状态:提前终止企业 / 申办者:Ensoma
药物 / 成分:MGTA-145、Plerixafor
登记的停止原因(原文):This study was voluntarily terminated due to a business decision not to proceed and not due to any safety issue
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
Perioperative Chemotherapy in Gastric Cancer
编号:NCT04937738登记状态:提前终止企业 / 申办者:Ukrainian Society of Clinical Oncology
药物 / 成分:Docetaxel、Oxaliplatin、Leucovorin、Fluorouracil
登记的停止原因(原文):High rate of disease progression in XELOX arm
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
编号:NCT05216510登记状态:提前终止企业 / 申办者:Tonix Pharmaceuticals, Inc.
药物 / 成分:TNX-2110、TNX-2120、TNX-2130、CANDIN
登记的停止原因(原文):Lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
编号:NCT05601466登记状态:提前终止企业 / 申办者:Institute of Hematology & Blood Diseases Hospital, China
药物 / 成分:QN-023a、Cyclophosphamid、Fludarabine、Cytarabine
登记的停止原因(原文):It did not reach the expected results of clinical trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
编号:NCT05601830登记状态:提前终止企业 / 申办者:Institute of Hematology & Blood Diseases Hospital, China
药物 / 成分:QN-030a、Cyclophosphamid、Fludarabine、Cytarabine
登记的停止原因(原文):It did not reach the expected results of clinical trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
编号:NCT06448364登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-07329640、sasanlimab、bevacizumab
登记的停止原因(原文):Strategic business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-05
Dosing of Ketorolac in the Emergency Department
编号:NCT03464461登记状态:提前终止企业 / 申办者:University of Missouri-Columbia
药物 / 成分:Ketorolac
登记的停止原因(原文):Pandemic related supply shortages and slowed enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-05
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
编号:NCT03635996登记状态:提前终止企业 / 申办者:Milestone Pharmaceuticals Inc.
药物 / 成分:Etripamil NS 70 mg、Aptar Pharma Nasal Spray Bidose System
登记的停止原因(原文):Study was stopped by the Sponsor
查看官方原始记录 ↗